Compare Natera Inc. Common Stock (NTRA) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Charles Schwab Corporation Common Stock — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Charles Schwab Corporation Common Stock trades at $97.44 (market cap $165.91B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 2.9× Natera Inc. Common Stock's market cap, and Charles Schwab Corporation Common Stock pays a 1.33% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Charles Schwab Corporation Common Stock for 86 Days on average.
| NTRA | SCHW | |
|---|---|---|
Market Cap | $57.03B | $165.91B |
Volume | 1,131,157 | 6,860,399 |
Sector | Health | Financials |
52-Week High | $425.64 | $113.65 |
52-Week Low | $179.42 | $85.35 |
Typical Hold Time | 0 Days | 86 Days |
Enterprise Value | $56.18B | $152.35B |
Dividend Yield | — | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Charles Schwab (SCHW) trades at $96.80, down 0.27% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported record quarterly revenue of $7.08 billion in Q3 2026 and has beaten earnings estimates for three consecutive quarters. Analyst consensus remains bullish with a $120.69 price target, representing 25% upside potential from current levels.
SCHW demonstrates robust financial health with 38.79% net margins and 22.45% ROE, though technical weakness and competitive pressures in brokerage services present near-term challenges. The stock offers attractive valuation at 17.48x P/E with strong earnings momentum, but investors should monitor interest rate sensitivity and market volatility impacts on trading volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
